Phase III trial in 407 patients with untreated advanced melanoma: adding the IO102-IO103 vaccine to pembrolizumab gave median PFS 19.4 vs 11.0 months (HR 0.77, P = 0.0558), missing statistical significance; grade 3+ treatment-related adverse events 14.5% vs 15.6%.
RCTn = 407
Hassel et al. IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma